Blood test may predict immunotherapy success in cancer patients
NCT ID NCT02840058
First seen Apr 24, 2026 · Last updated May 15, 2026 · Updated 2 times
Summary
This study looked at whether measuring a specific type of immune response (anti-telomerase T cells) in the blood can help predict how well cancer immunotherapy (anti-PD1/PDL1) will work. Researchers enrolled 295 adults with advanced or metastatic cancer who were about to start this treatment. The goal was to see if this immune marker could forecast treatment effectiveness, potentially helping doctors personalize cancer care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Nord Franche-Comté
Montbéliard, 25200, France
-
Hôpital Saint-Louis - APHP
Paris, France
-
Institut Paoli Calmette
Marseille, France
-
University Hospital of Besançon
Besançon, 25000, France
Conditions
Explore the condition pages connected to this study.